title: Coxiella burnetii antibody prevalences among human populations in north-east Africa determined by enzyme immunoassay.
abstract: Retrospective serosurveys were conducted to determine the prevalence of antibody to phase-I Coxiella burnetii among humans in various locations of north-east Africa. Sera were tested by the enzyme immunoassay (EIA). Initially the EIA was compared with the standard indirect fluorescent antibody (IFA) method for the detection of antibody to C. burnetii. Results indicated that the EIA was slightly less sensitive (88%), but highly specific (94%) and less subjective than the IFA technique. EIA was subsequently adopted for estimating prevalences in the studied human populations. Data obtained by EIA indicated that the prevalence of C. burnetii antibody among adult Egyptian blood donors was 20% (n = 358) in the Suez Canal area, 16% (n = 501) in the Nile Valley and 10% (n = 427) in the Nile Delta. Among adult patients with acute, undifferentiated fever in Egypt, the prevalence was 28% (n = 50) of acute sera, with seroconversion in 12% of convalescent sera. Antibody to C. burnetii was detected by EIA in the sera of 25% (n = 71) of cattle workers in Egypt, 10% (n = 100) of housewives in Sudan, and 37% (n = 104) of adults in north-west Somalia. Following a fever outbreak affecting all ages in northern Sudan, IgG antibody to C. burnetii was present in 54% of the febrile persons (n = 185) and in 53% of afebrile persons (n = 186). IgM antibody to C. burnetii was demonstrated in 29% of the febrile persons and 15% of the afebrile persons. These results implicate C. burnetii as a possibly important and under-reported cause of human disease and undiagnosed fevers in north-east Africa.
authors.affiliation: Virology Division, US Naval Medical Research Unit No. 3, Cairo, Egypt.
authors.forename: B A
authors.initials: BA
authors.lastname: Botros
authors.forename: A K
authors.initials: AK
authors.lastname: Soliman
authors.forename: A W
authors.initials: AW
authors.lastname: Salib
authors.forename: J
authors.initials: J
authors.lastname: Olson
authors.forename: R G
authors.initials: RG
authors.lastname: Hibbs
authors.forename: J C
authors.initials: JC
authors.lastname: Williams
authors.forename: M
authors.initials: M
authors.lastname: Darwish
authors.forename: A
authors.initials: A
authors.lastname: el Tigani
authors.forename: D M
authors.initials: DM
authors.lastname: Watts
mesh_terms: D000328:Adult; D000352:Africa, Northern / Q000453:epidemiology; D000914:Antibodies, Viral / Q000097:blood*; D001782:Blood Donors; D016997:Coxiella burnetii / Q000276:immunology*; D004196:Disease Outbreaks; D004534:Egypt / Q000453:epidemiology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D015995:Prevalence; D011778:Q Fever / Q000453:epidemiology* / Q000276:immunology; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
chemical_list: D000914:Antibodies, Viral